Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Squamous Cell
  • Lung Neoplasms

abstract

  • The 13% partial response rate observed did not meet the prespecified response threshold to pursue further study of the combination of gefitinib and everolimus. The response rate in patients with non-EGFR mutant tumors was 8%, likely reflecting activity of everolimus. Further investigation of mammalian target-of-rapamycin inhibitors in patients with NSCLC with KRAS G12F-mutated tumors is warranted.

publication date

  • October 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4020424

Digital Object Identifier (DOI)

  • 10.1097/JTO.0b013e3181ec1531

PubMed ID

  • 20871262

Additional Document Info

start page

  • 1623

end page

  • 9

volume

  • 5

number

  • 10